Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Primary thrombocytosis in children.

Kucine N, Chastain KM, Mahler MB, Bussel JB.

Haematologica. 2014 Apr;99(4):620-8. doi: 10.3324/haematol.2013.092684. Review.

2.

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T.

Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):849.

3.

Thrombocytosis and thrombocythemia.

Schafer AI.

Blood Rev. 2001 Dec;15(4):159-66. Review.

PMID:
11792116
4.

Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.

Dua V, Yadav SP, Kumar V, Saxena R, Sachdeva A.

Int J Hematol. 2012 Dec;96(6):810-3. doi: 10.1007/s12185-012-1193-8. Epub 2012 Oct 7.

PMID:
23054653
5.

[Thrombocytosis and thrombocythemia].

Lefrère JJ, Samama M.

Rev Med Interne. 1985 Jun;6(3):285-90. French. No abstract available.

PMID:
4048690
6.

Myeloproliferative neoplasms.

Publicover A, Medd P.

Clin Med (Lond). 2013 Apr;13(2):188-92. doi: 10.7861/clinmedicine.13-2-188.

PMID:
23681871
7.

Essential thrombocythaemia.

Harrison CN, Green AR.

Best Pract Res Clin Haematol. 2006;19(3):439-53. Review.

PMID:
16781482
8.

Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome.

Giona F, Teofili L, Moleti ML, Martini M, Palumbo G, Amendola A, Mazzucconi MG, Testi AM, Pignoloni P, Orlando SM, Capodimonti S, Nanni M, Leone G, Larocca LM, Foà R.

Blood. 2012 Mar 8;119(10):2219-27. doi: 10.1182/blood-2011-08-371328. Epub 2012 Jan 18.

9.

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR.

Haematologica. 2011 Oct;96(10):1462-9. doi: 10.3324/haematol.2011.045591. Epub 2011 Jun 28.

10.

JAK2 mutation-negative essential thrombocythemia in a child presenting with cerebral venous thrombosis.

Khan AA, Kumar V, Anand I, Kumar M, Sharma P, Bhargava M.

Hematol Oncol Stem Cell Ther. 2012;5(1):66-8. doi: 10.5144/1658-3876.2012.66.

11.

Management of MPN beyond JAK2.

Harrison CN, Garcia NC.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):348-54. doi: 10.1182/asheducation-2014.1.348. Epub 2014 Nov 18. Review.

PMID:
25696878
12.

Idiopathic myelofibrosis in children: primary myelofibrosis, essential thrombocythemia, or transient process?

Slone JS, Smith MC, Seegmiller AC, Sidonio RF, Yang E.

J Pediatr Hematol Oncol. 2013 Oct;35(7):559-65. doi: 10.1097/MPH.0b013e31829cdea0.

PMID:
23799525
13.

Guideline for investigation and management of adults and children presenting with a thrombocytosis.

Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, Erber W, Everington T, Green AR, Hall GW, Hunt BJ, Ludlam CA, Murrin R, Nelson-Piercy C, Radia DH, Reilly JT, Van der Walt J, Wilkins B, McMullin MF; British Committee for Standards in Haematology.

Br J Haematol. 2010 May;149(3):352-75. doi: 10.1111/j.1365-2141.2010.08122.x. Epub 2010 Mar 15. Review. No abstract available.

PMID:
20331456
14.

Persistent thrombocytosis in elderly patients with rare hyposplenias that mimic essential thrombocythemia.

Imashuku S, Kudo N, Kubo K, Takahashi N, Tohyama K.

Int J Hematol. 2012 Jun;95(6):702-5. doi: 10.1007/s12185-012-1082-1. Epub 2012 Apr 24.

PMID:
22527856
15.

Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.

Turakhia SK, Murugesan G, Cotta CV, Theil KS.

J Clin Pathol. 2016 Aug;69(8):713-9. doi: 10.1136/jclinpath-2015-203498. Epub 2016 Jan 11.

PMID:
26754830
16.

Essential thrombocythaemia in children: is a treatment needed?

Randi ML, Putti MC.

Expert Opin Pharmacother. 2004 May;5(5):1009-14.

PMID:
15155103
17.
18.

EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.

Wernig G, Kharas MG, Mullally A, Leeman DS, Okabe R, George T, Clary DO, Gilliland DG.

Leukemia. 2012 Apr;26(4):720-7. doi: 10.1038/leu.2011.261. Epub 2011 Oct 18.

PMID:
22005786
19.

New advances in the pathogenesis and therapy of essential thrombocythemia.

Levine RL, Heaney M.

Hematology Am Soc Hematol Educ Program. 2008:76-82. doi: 10.1182/asheducation-2008.1.76. Review.

PMID:
19074062
20.

Pathogenesis and management of essential thrombocythemia.

Beer PA, Green AR.

Hematology Am Soc Hematol Educ Program. 2009:621-8. doi: 10.1182/asheducation-2009.1.621. Review.

PMID:
20008247

Supplemental Content

Support Center